Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 7/20 | 0.32 |
| ▸ | MYC | P01106 | 2/20 | 0.30 |
| ▸ | WDR5 | P61964 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20137953 | 0.94 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL20138127 | 0.87 | MEN1 (0.34) | MEN1KMT2ATSHR | |
| SCHEMBL20138017 | 0.86 | MEN1 (0.33) | SMN1; SMN2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL20138182 | 0.85 | NR1H2 (0.34) | SMN1; SMN2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL20138288 | 0.85 | MEN1 (0.34) | SMN1; SMN2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL20137998 | 0.84 | KCNH2 (0.33) | MEN1KMT2ATSHRMYCWDR5 | |
| SCHEMBL20137920 | 0.84 | MEN1 (0.34) | MEN1KMT2ATSHR | |
| SCHEMBL20138176 | 0.83 | REN (0.31) | MEN1KMT2A | |
| SCHEMBL20138086 | 0.82 | NR1H2 (0.32) | — | |
| SCHEMBL18305093 | 0.81 | NR1H2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | SMN1; SMN2 798/4885ALDH1A1 557/4885MEN1 4094/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | SMN1; SMN2 419/4885ALDH1A1 244/4885MEN1 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.